Further Expansions and Positive Study Results Drive Healthcare Companies - Research Report on Agilent, Thermo Fisher, BG Medicine, Quest Diagnostics, and Ironwood Pharmaceuticals PR Newswire NEW YORK, May 31, 2013 NEW YORK, May 31, 2013 /PRNewswire/ -- Editor Note: For more information about this release, please scroll to bottom. Today, Wall Street Reports announced new research reports highlighting Agilent Technologies Inc. (NYSE: A), Thermo Fisher Scientific Inc. (NYSE: TMO), BG Medicine, Inc. (NASDAQ: BGMD), Quest Diagnostics Inc. (NYSE: DGX), and Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD). Today's readers may access these reports free of charge - including full price targets, industry analysis and analyst ratings - via the links below. Agilent Technologies Inc. Research Report On May 28, 2013, Agilent Technologies Inc. (Agilent) expanded its presence in Vietnam by announcing the opening of two new offices. Located in Hanoi and Ho Chi Minh City, these offices will be fully equipped and staffed to provide customers in Vietnam with sales, applications and support services. In Hanoi, Agilent's Advantage Services Facility, a repair and calibration center for electronic test instruments, will serve customers spanning industries such as government, defense, education, and manufacturing. Agilent's Technology Demo Center in Ho Chi Minh City will be equipped with cutting-edge bio-analytical instruments used by scientists and researchers, enabling the Company to collaborate with customers in Vietnam to develop applications and methodologies for research and commercial implementations in the life sciences and chemical analysis industries. Dr. Nick Roelofs, Agilent's Life Sciences Group President, commented, "As one of the fastest developing infrastructure and business regions in the world, Vietnam is a critical component in Agilent's key emerging markets strategy. We look forward now to directly participating with customers to deliver the products and solutions in electronics, chemical analysis and life sciences that will help accelerate their work and ultimately contribute to the growth of Vietnam." The Full Research Report on Agilent Technologies Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.wsreports.com/r/full_research_report/075f_A] -- Thermo Fisher Scientific Inc. Research Report On May 23, 2013, Thermo Fischer Scientific Inc.'s (Thermo Fisher) Board of Directors declared a quarterly cash dividend of $0.15 per share. The dividend will be paid on July 15, 2013 to shareholders of record as of June 17, 2013. The Full Research Report on Thermo Fisher Scientific Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.wsreports.com/r/full_research_report/45ea_TMO] -- BG Medicine, Inc. Research Report On May 28, 2013, BG Medicine, Inc. (BG Medicine) announced the presentation of new clinical research data on the BGM Galectin-3 test in heart disease at the 2013 European Society of Cardiology Heart Failure Congress (ESC-HF) in Lisbon, Portugal. Among the highlights was a late-breaking oral presentation of results from the Aldo-DHF Biomarker Substudy, which demonstrated the usefulness of galectin-3 testing for assessing functional capacity and clinical prognosis in patients diagnosed with a form of heart failure known as Heart Failure with Preserved Ejection Fraction (HFpEF). HFpEF is the fastest growing type of clinical heart failure in the United States and Europe, disproportionately affecting women and accounting for one-third to one-half of all hospital admissions for heart failure. Paul Sohmer, President and CEO of BG Medicine, stated, "The data presented at ESC-HF further demonstrate that galectin-3 may be an important determinant of heart failure risk across the clinical spectrum of disease. Unplanned hospitalizations of patients with heart failure are a major cost burden on healthcare systems, particularly among patients with a diagnosis of HFpEF, one of the fastest growing but most difficult types of heart failure to identify and treat. The data presented at ESC-HF suggest that galectin-3 testing may help to identify HFpEF patients who are at risk of near-term adverse events." The Full Research Report on BG Medicine, Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.wsreports.com/r/full_research_report/e185_BGMD] -- Quest Diagnostics Inc. Research Report On May 21, 2013, world's leading provider of diagnostic services, Quest Diagnostics Inc. (Quest Diagnostics), announced that its Board of Directors declared a quarterly cash dividend of $0.30 per share. The dividend is payable on July 17, 2013 to the shareholders of record as of July 2, 2013. The Full Research Report on Quest Diagnostics Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.wsreports.com/r/full_research_report/0cb6_DGX] -- Ironwood Pharmaceuticals, Inc. Research Report On May 21, 2013, Ironwood Pharmaceuticals, Inc. (Ironwood Pharmaceuticals) announced the pricing of an underwritten public offering of 10.5 million shares of its Class A common stock at a price of $13 per share to the public. The gross proceeds to Ironwood Pharmaceuticals from this offering are expected to be approximately $136.5 million, before deducting underwriting discounts and commissions, and other estimated offering expenses payable by the Company. The offering is expected to close on May 24, 2013, subject to the satisfaction of customary closing conditions. The Company plans to use the net proceeds from this offering to support the launch of LINZESS (linaclotide) in the US and to fund additional linaclotide development opportunities to strengthen the clinical profile of LINZESS. The Full Research Report on Ironwood Pharmaceuticals, Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.wsreports.com/r/full_research_report/d5cb_IRWD] ---- EDITOR NOTES: 1.This is not company news. We are an independent source and our views do not reflect the companies mentioned. 2.Information in this release is fact checked and produced on a best efforts basis and reviewed by a CFA. However, we are only human and are prone to make mistakes. If you notice any errors or omissions, please notify us below. 3.This information is submitted as a net-positive to companies mentioned, to increase awareness for mentioned companies to our subscriber base and the investing public. 4.If you wish to have your company covered in more detail by our team, or wish to learn more about our services, please contact us at pubco@EquityNewsNetwork.com. 5.For any urgent concerns or inquires, please contact us at compliance@EquityNewsNetwork.com. 6.Are you a public company? Would you like to see similar coverage on your company? Send us a full investors' package to research@EquityNewsNetwork.com for consideration. COMPLIANCE PROCEDURE Content is researched, written and reviewed on a best-effort basis. This document, article or report is prepared and authored by Equity News Network. An outsourced research services provider has, through Chartered Financial Analysts, only reviewed the information provided by Equity News Network in this article or report according to the Procedures outlined by Equity News Network. Equity News Network is not entitled to veto or interfere in the application of such procedures by the outsourced provider to the articles, documents or reports, as the case may be. NOT FINANCIAL ADVICE Equity News Network makes no warranty, expressed or implied, as to the accuracy or completeness or fitness for a purpose (investment or otherwise), of the information provided in this document. This information is not to be construed as personal financial advice. Readers are encouraged to consult their personal financial advisor before making any decisions to buy, sell or hold any securities mentioned herein. NO WARRANTY OR LIABILITY ASSUMED Equity News Network is not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted by Equity News Network whatsoever for any direct, indirect or consequential loss arising from the use of this document. Equity News Network expressly disclaims any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Equity News Network does not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice. SOURCE Wall Street Reports Contact: WSReports.com, +1-310-496-8071
Further Expansions and Positive Study Results Drive Healthcare Companies - Research Report on Agilent, Thermo Fisher, BG
Press spacebar to pause and continue. Press esc to stop.